Role of micronised progesterone in maintenance therapy following arrested preterm labor: a randomised controlled trial


  • Gitika Shankar Mishra Department of Obstetrics & Gynaecology, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, MH, India
  • S. A. Inamdar Department of Obstetrics & Gynaecology, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, MH, India


Preterm labor, Birth weight, Latency period, NICU admissions


Background: The aims and objectives of this study were to determine whether maintenance tocolytic therapy with micronised progesterone (400 mg) in patients with arrested preterm labor, prolongs the latency period of gestation and to see the effect of prolonged latency period on fetal outcome in terms of birth weight and NICU admissions and maternal outcome in terms of prolongation to term gestation.

Methods: Pregnant women who were arrested with acute tocolysis as evidenced by a 12 hour contraction free period were randomized into study and control groups. The study group received 400 mg of vaginal micronized progesterone daily, while the control group did not receive any drug. The patients were followed up till 37 completed weeks. Prolongation of pregnancy upto term and birth wt. and NICU admissions were noted.

Results: 1) In the present study the mean period of gestation at delivery was significantly high in study group 37.51 ± 2.70 weeks as compared to that in control group 35.15 ± 2.72 weeks. This was statistically significant at 95% confidence interval by using student’s t statistics. 2) In the present study, 42.00% babies in study group had birth weight more than 2.5 kg which was significantly higher than that in control group, in which 24.00% had birth weight more than 2.5 kg.

Conclusions: We conclude that, maintenance tocolytic therapy with micronised progesterone (400 mg) up-to 37 weeks of gestation in patients with arrested preterm labor significantly prolongs the latency period and results in better perinatal outcome.



Steer P. The epidemiology of preterm labor. BJOG. 2005;112(Suppl 1):1-3.

Goldenberg RL. The management of preterm labor. Obstet Gynaecol. 2002;100(5 pt.1):1020-37.

Dodd JM, Crowther CA. The role of progesterone in prevention of preterm birth. Int J Womens Health. 2009;1:73-84.

H. Blencowe, Simon Cousens, Doris Chou, Mikkd Ostergaard. Born too soon: the global epidemiology of 15 million preterm birth. Reprod Health. 2013;10(Suppl):s2.

Chnandraharan E, Arulkumaran S. Recent advances in management of preterm labor. J Obstet Gynaecol India. 2005;55(2):118-24.

Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2008;48(1):58-63.

Vause S, Johnston T. Management of preterm labour. Arch Dis Child Fetal Neonat Ed. 2000 Sep;83(2):F75-85.

de heus R, Mulder EJ, Visser GH. Management of preterm labor: atosiban or nifedipine? Int J Womens Health. 2010;2:137-42.

Raman Wilms L, Tseng AL, Wighdart S, Emarson TR, Korean G. Fetal genital effect of 1st trimester sex hormone exposure a meta-analysis. Obstet Gynaecol. 1995;85:141-9.

S Chardein JL. Congenital abnormalities and hormones during pregnancy clinical review. Teratology. 1980;22:251-70.

Blencowe H, Cousens S, Oestergaard M, Chou D, Moller AB, N Arwarl R, et al. National Regional and worldwide estimates of preterm birth. Lancet. 2012. Jun;379(9832):2162-72.

Bowen R. Placental hormones, 2000. Available at: Accessed 12 March 2008.

Vaja Pradyuman, Goyal Mekhla. A comparative study of two tocolytic agents for inhibition of preterm labour. Gujarat Medical J. 2014 Mar;69(1):28-31.

Singh Nisha, Singh Uma, Seth Shikha. Comparative study of nifedipine and isoxuprine as tocolytics for preterm labor. J Obstet Gynaecol India. 2011 Sep-Oct;61(5):512-5.

Saifon Chawanpaiboon, Sujin Kanokpongsakdi. Preterm birth at Siriraj hospital: a 9-year period review (2002-2010). Thailand Siriraj Med J. 2011;63:143-6.






Original Research Articles